M&A Deal Summary |
|
|---|---|
| Date | 2025-03-19 |
| Target | Emergent BioSolutions - Baltimore-Bayview Drug Substance Manufacturing Site |
| Sector | Life Science |
| Buyer(s) | Syngene International |
| Sellers(s) | Emergent BioSolutions |
| Deal Type | Divestiture |
| Deal Value | 37M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1993 |
| Sector | Life Science |
| Employees | 6,510 |
| Revenue | 33.7B INR (2024) |
Syngene International is a custom research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. Syngene International was founded in 1993 and is based in Bengaluru, Karnataka.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2025) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1998 |
| Sector | Healthcare Services |
| Employees | 1,600 |
| Revenue | 1.0B USD (2023) |
Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent BioSolutions was founded in 1998 and is based in Gaithersburg, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector (Life Science) | 2 of 2 |
| Type (Divestiture) | 2 of 2 |
| Country (United States) | 1 of 1 |
| Year (2025) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-08-28 |
Adapt Pharma Operations
Dublin 2, Ireland ADAPT Pharma, Inc. is solely focused on helping address the opioid overdose and addiction crisis. It distributes NARCAN® (naloxone HCl) Nasal Spray, the major FDA approved emergency treatment for opioid overdose, to health agencies, first responders and retail pharmacies. It also has a development pipeline of potential opioid overdose and addiction treatment options. Emergent is a leader in the development, supply and provision of medical countermeasures for accidental, intentional and naturally occurring public health threats as well as emerging infectious diseases. |
Buy | $735M |
